公开(公告)号：US20210079055A1

公开(公告)日：2021-03-18

申请号：US15930057

申请日：2020-05-12

Applicant: The Board of Trustees of the Leland Stanford Junior University ,  United States Department of Health and Human Services, Office of Technology Transfer, National Insti

Inventor： Christopher K. Garcia ,  Suman Mitra ,  Warren J. Leonard ,  Aaron M. Ring

IPC: C07K14/55 ,  A61K38/00

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor and a decreased binding capacity for IL-2Rγc receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

公开(公告)号：US10654905B2

公开(公告)日：2020-05-19

申请号：US16175709

申请日：2018-10-30

Applicant: The Board of Trustees of the Leland Stanford Junior University ,  United States Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health

Inventor： Christopher K. Garcia ,  Suman Mitra ,  Warren J. Leonard ,  Aaron M. Ring

IPC: A61K38/20 ,  C07K14/55 ,  A61K38/00

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor and a decreased binding capacity for IL-2Rγc receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

公开(公告)号：US10590074B2

公开(公告)日：2020-03-17

申请号：US15830244

申请日：2017-12-04

Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health

Inventor： Amy Hauck Newman ,  Oluyomi M. Okunola-Bakare ,  Jianjing Cao

IPC: C07C323/60 ,  A61K45/06 ,  A61K31/135 ,  C07C317/44 ,  C07C317/28 ,  C07C323/25 ,  C07D295/08 ,  C07D295/088 ,  C07D295/108 ,  C07D295/185

Abstract: Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.

公开(公告)号：US20040214995A1

公开(公告)日：2004-10-28

申请号：US10685977

申请日：2003-10-15

Applicant: Government of the United States of America, represented by the Secretary, Department of Health ,  and Human Services Office of Technology Transfer

Inventor： Yutaka Kawakami ,  Steven A. Rosenberg

IPC: C07K016/30

CPC classification number: C07K14/47 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/4748 ,  G01N33/5743

Abstract: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.

Abstract translation: 本发明提供编码被称为MART-1的T淋巴细胞识别的黑素瘤抗原的核酸序列。 本发明还涉及使用本发明的核酸序列，蛋白质或抗体诊断，评估或预测患有黑素瘤或转移性黑素瘤的哺乳动物的生物测定。 本发明还提供衍生自MART-1黑素瘤抗原的免疫原性肽和称为gp100的第二黑素瘤抗原。 本发明还提供衍生自MART-1黑素瘤抗原或gp100抗原的免疫原性肽，其已被修饰以增强其免疫原性。 所提供的蛋白质和肽可以作为预防或治疗黑素瘤的免疫原或疫苗。

公开(公告)号：US20190119346A1

公开(公告)日：2019-04-25

申请号：US16175709

申请日：2018-10-30

Applicant: The Board of Trustees of the Leland Stanford Junior University ,  United States Department of Health and Human Services, Office of Technology Transfer, National

Inventor： Christopher K. Garcia ,  Suman Mitra ,  Warren J. Leonard ,  Aaron M. Ring

IPC: C07K14/55 ,  A61K38/00

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor and a decreased binding capacity for IL-2Rγc receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

公开(公告)号：US10001483B2

公开(公告)日：2018-06-19

申请号：US15192819

申请日：2016-06-24

Applicant: Celgene Corporation ,  The United States of America, as represented by the Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health

Inventor： Robert Yarchoan ,  Jerome B. Zeldis ,  Mark N. Polizzotto ,  David A. Davis ,  Irini Sereti ,  Thomas S. Uldrick ,  Denise Whitby ,  Vikram Khetani

IPC: A61K31/40 ,  G01N33/574 ,  A61K31/454 ,  A61K45/06 ,  A61K31/704 ,  A61K31/4035

CPC classification number: G01N33/57407 ,  A61K31/4035 ,  A61K31/454 ,  A61K31/704 ,  A61K45/06 ,  A61P35/00 ,  G01N2333/70539 ,  G01N2800/52 ,  A61K2300/00

Abstract: Provided herein are uses of gene and protein biomarkers as a predictor of clinical sensitivity of Kaposi's sarcoma (KS) or Kaposi's sarcoma-associated herpesvirus (KSHV) induced lymphoma and patient response to treatment with an immunomodulatory compound. Further provided herein are methods for the treatment or management of Kaposi's sarcoma or KSHV-induced lymphoma with an immunomodulatory compound, alone or in combination with doxorubicin.

公开(公告)号：US09874622B2

公开(公告)日：2018-01-23

申请号：US14038948

申请日：2013-09-27

Applicant: General Electric Company ,  The United States of America, As Represented By The Secretary, Department of Health and Human Services Office of Technology Transfer, National Institutes of Health

Inventor： Timothy William Skloss ,  Jonathan Alan Murray ,  Jan Henrik Ardenkjaer-Larsen ,  Murali K. Cherukuri ,  Marcelino Bernardo ,  Nallathamby Devasahayam

IPC: G01R33/28 ,  G01R33/56 ,  A61B5/055

CPC classification number: G01R33/5601 ,  A61B5/055 ,  A61B2560/06 ,  G01R33/282

Abstract: A system and method for transporting a hyperpolarized substance is disclosed. A transport vessel for transporting such a hyperpolarized substance includes a vessel housing, a chamber formed within the vessel housing that is configured to receive a container holding a hyperpolarized substance, and an electromagnet configured to generate a magnetic containment field about the chamber when a current is supplied thereto, the magnetic containment field comprising a homogeneous magnetic field. The transport vessel also includes a non-magnetic power source to supply the current to the electromagnet and a control circuit configured to selectively interrupt the supply of current to the electromagnet so as to control generation of the magnetic containment field, with the transport vessel being magnetically inert when the supply of current to the electromagnet is interrupted by the control circuit.

公开(公告)号：US09696534B2

公开(公告)日：2017-07-04

申请号：US14380392

申请日：2013-02-22

Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INTITUTES OF HEALTH ,  Hari Shroff ,  Andrew York

Inventor： Hari Shroff ,  Andrew York

IPC: G01N21/64 ,  G02B21/00

CPC classification number: G02B21/0072 ,  G01N21/6458 ,  G01N2021/6478 ,  G01N2201/0633 ,  G02B21/0032 ,  G02B21/0036 ,  G02B21/004 ,  G02B21/0076

Abstract: A multi-focal selective illumination microscopy (SIM) system for generating multi-focal patterns of a sample is disclosed. The multi-focal SIM system performs a focusing, scaling and summing operation on each multi-focal pattern in a sequence of multi-focal patterns that completely scan the sample to produce a high resolution composite image.

公开(公告)号：US11426415B2

公开(公告)日：2022-08-30

申请号：US16491826

申请日：2018-03-06

Applicant: Washington University ,  The United States of America, As Represented by the Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health

Inventor： Fumihiko Urano ,  Jana Mahadevan ,  Amy Clark ,  Ajit Jadhav ,  David Maloney ,  Brandon Harvey ,  Shyh-ming Yang ,  Mark Henderson

IPC: A61K31/554 ,  A61K9/00 ,  A61K31/155 ,  A61K31/4178 ,  A61K31/4985 ,  A61K45/06 ,  C07K14/605

Abstract: The present invention generally relates to compositions and methods for treating or preventing an endoplasmic reticulum stress disorder in subjects, including compositions and methods for treating or preventing Wolfram syndrome. The present invention also relates to methods for treating symptoms of neurodegenerative diseases.

公开(公告)号：US11384131B2

公开(公告)日：2022-07-12

申请号：US15930057

申请日：2020-05-12

Applicant: The Board of Trustees of the Leland Stanford Junior University ,  United States Department of Health and Human Services, Office of Technology Transfer, National Institutes of Heath

Inventor： Christopher K. Garcia ,  Suman Mitra ,  Warren J. Leonard ,  Aaron M. Ring

IPC: A61K38/00 ,  C07K14/55

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor and a decreased binding capacity for IL-2Rγc receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.